G2GBIO Good to the Globe Biotech Company
For eight years since its inception in March 2017, G2GBIO has applied for 171 patents, including 38 domestic, applications for 110 overseas individual countries and 23 PCT. To date, 65 applications were registered, including 44 international and 21 domestic patents, with the rest being pending or under review.
-
Innovative Long-Acting Microsphere Platform (InnoLAMP): Drug Development and Manufacturing TechnologyInnoLAMP uses biodegradable polymers to create cutting-edge injectable microspheres. Our technology ensures precise drug delivery and prolonged body-wise activity, all while being cost-effective and highly sustainable, promising particularly effective commercialization processes. -
Application of InnoLAMP TechnologyInnoLAMP technology enhances drug sustainability, perfect for chronic disease management and simplifying administration. As lifespans increase, our technology offers crucial convenience for elderly and chronically ill patients, while also reducing the side effects associated with long-term drug use. -
InnoLAMP PatentsG2GBIO's patented InnoLAMP technology excels in mass-producing uniform microsphere drug injectables with sustained release and high reproducibility. Suitable for peptides, small molecules, and various indications, it offers a cost-effective solution to meet global demand for high-quality, sustained-release drugs. We are committed to meeting global demand for cost-effective, sustained-release drug solutions with unparalleled quality and efficiency. -
Innovative Drug Delivery Systems for Advanced TherapeuticsG2GBIO has achieved preclinical drug release profiles for its target product (e.g. GB-5001) and consistent Phase 1 clinical trial results, which proved that our advanced technology minimizes injection site pain and enhances bioavailability, distinguishing our microsphere injectables from the competition. -
Diverse Drug PipelineG2GBio’s R&D pipeline focuses on treatments for Alzheimer’s, Type 2 diabetes, post-operative pain, Schizophrenia with several drugs already in clinical trials or preparation for clinical studies. Through strategic partnerships with global pharmaceutical companies, we plan to significantly expand our pipeline, leveraging InnoLAMP technology for future drug development. -
Emphasis on R&DIn May 2022, G2GBIO completed its 4,177㎡ research center in Osong BioValley, featuring a larger scale facility. Led by a team of experts, including the CEO with deep expertise in sustained-release technology also actively engaged in research and development. Due to their dedication, G2GBIO has quickly achieved significant R&D milestones. Moving forward, we remain committed to prioritizing R&D as the key to our mission: delivering quality medicines to improve lives worldwide. -
Strategic Partnerships and Licensing AgreementsG2GBIO’s dynamic R&D progress has secured several significant joint development and licensing agreements. We’re partnering with Korea Pharma and Humedix on sustained-release injectables for Alzheimer’s Disease, with Hanwha Pharma on hepatitis B sustained-release injectables, and with Keyfron Bio on veterinary medicines. We are also exploring further strategic partnerships for other pipeline drugs. G2GBIO remains committed to pursuing these collaborations drive sustainable growth and innovation.
CEO'S MESSAGE
G2GBIO, a company founded with the entrepreneurial spirit of Human First Respect for Life by Providing Good Medicines
As the global aging population continues to grow, the prevalence of chronic diseases like dementia, diabetes, and arthritis increases, driving demand for Long-Acting Injectables (LAIs) that enhance medication convenience and adherence.
LAIs are emerging as a key solution for managing these conditions, offering benefits such as improved patient compliance and reduced treatment costs.
LAIs not only align with the goals of healthy aging but also provide significant financial advantages compared to developing new drugs from scratch, costing roughly one-tenth as much and taking less than half the time.
Despite these benefits, commercial production of sustained-release pharmaceuticals faces high entry barriers.
G2GBIO is addressing this challenge by advancing treatments for chronic diseases through our proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) technology.
We are very proud that our unique approach ensures the production of high-quality, uniform microsphere injectables on a commercial scale.
With InnoLAMP, G2GBIO is well-positioned to expand globally and continuously innovate, aiming to bring new, effective drugs to the market.
We are committed to driving progress and enhancing patient care worldwide.
Thank you.
Heeyong Lee
HISTORY
2017-Present
- May-
- Registered U.S. patent for semaglutide
- Jan-
- Registered formulation patent for GB-5021 (schizophrenia treatment)
- Aug-
- Listed on KOSDAQ (IPO)
- Jul-
- Selected for the Ministry of Trade, Industry and Energy's long-acting immunosuppressant formulation development project
- Jun-
- Filed patent for microsphere process improvement
- Mar-
- Filed formulation patent for GB-5021 (schizophrenia treatment)
- Aug-
- Passed the Technology Evaluation for KOSDAQ Technology Special Listing
- Jul-
- Signed an MOU for CDMO Services of Long-Acting Injectable Drugs Received Approval for Phase 1 Clinical Trial Plan for Alzheimer’s Treatment in Korea
- Apr-
- elected for the Ministry of SMEs and Startups Project for Formulation Development and Technology Commercialization of Long-Acting Schizophrenia Treatments
- Jan-
- Submitted IND Application for Phase 2 Clinical Trial of GB-2006 (Postoperative Pain Relief for Animals) in Korea
- Dec-
-
Attracted Pre-IPO Investment
Completed Phase 1 Clinical Trial for GB-5001 (Alzheimer's Disease Medication) in Canada
- Nov-
- Initiated Phase 1 Clinical Trial for GB-5001 in Korea
- Oct-
-
Received the Minister's Award from the Ministry of SMEs and Startups (MSS) in the Small Business Technology Innovation Competition
Initiated Phase 1 Clinical Trial for GB-6002 (Postoperative Pain Medicine) in Korea
Phase 1 Clinical Trial Plan Approved by the Ministry of Food and Grug Safety (MFDS) for GB-5001
- Sep-
- IND Application Approved by the MFDS for Phase 1 Clinical Trial with GB-6002
- Mar-
- IND Application Approved by the MFDS for Phase 1 Clinical Trial with GB-5001
- Dec-
- Attracted Series C investments (a total of 14.6 billion won)
- Oct-
-
Selected for the Korea-UK international joint technology development project selected
Contracted Domestic Licensing with Humedix and Koreapharma for the Alzheimer's Disease Long-Acting Injectables 08
- Aug-
- Initiated Phase 1 Clinical Trial for a Long-Acting Alzheimer's Disease Drug in Canada
- Jul-
- Selected as a Co-Research Institute for the MSS’ Industry-Academy Platform Technology Development Project
- Jun-
- Participated in the MFDS Research to Establish a Synthetic Peptide Drug Evaluation System
- May-
- Established a New R&D Center in Osong
- Mar-
- Agreed upon Collaboration with Hanwha for HBV Development
- Jan-
- Participated in the MSS' Innovation Sector Startup Package (BIG3) Project
- Oct-
- MOU with Humedix on the development of sustained-release injectable GB-5001 Canada Phase 1 clinical trial approved
- Aug-
- MOU with Samyang Holdings on the development of sustained-release injectable
- Jul-
- Selected by the MOHW for an R&D Project Linked to Healthcare and Medical Investment Infrastructure (Government Project)
- May-
- Agreed with Keyfron Bio (Biotoxtech Subsidiary) upon Joint Development for Veterinary Medicines
- Feb-
- Attracted Bridge Investments from the SI, FI, and KIBO the Government Agency (a total of 2 billion won)
- Jul-
- Selected by the MSS for the Start-up Growth Support in the Innovative Field (BIG3, Government project)
- Jun-
- Attracted Series B Investments from seven institutes (a total of 11.4 billion won)
- Jan-
- Establishment of the GMP facility
- Jul-
- Agreed with Chungnam National University Hospital for Regional Hub Innovative Physician-Scientist Collaborative Research
- Jun-
- Selected by the MSS for a Preliminary Industry-Academia-Research Collaboration Project
- Apr-
-
Selected by the MOHW for Domestic KDRC (Government project)
Selected by the MOTIE for a Promising Bio IP Project (Government project)
Attracted Series A Investments (a total of 8 billion won) from 6 Institutes
- Dec-
- Selected for a High-Tech Medical Complex Base Technology Construction Project
- Jul-
- Selected by the SMBA for K-startup
- Mar-
- Established G2G Bio Co., Ltd.
Office Building
G2GBIO completed the construction of a new office building in Osong in May 2022, designed to offer an exceptional working environment for our team. The facility includes state-of-the-art research and development facilities to support our innovative projects
Organizational Diagram
G2GBIO will maintain sustainable management driven by the principles of TOP STARS*
(*TO= together ; P= precision ; S= speed ; T= trust ; A= active ; R= responsibility ; S= self-development)
ADDRESS
Head Office
- Address
- 21, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do S.Korea
- Phone
- (+82) 043.270.6000
- contactus@g2gbio.com
Office (Seoul)
- Address
- Room 401, Plaza 654 Building, 551 Eonju-ro, Gangnam-gu, Seoul S.Korea
- Phone
- (+82) 043.270.6000
- contactus@g2gbio.com
GMP facility
- Address
- 123, Osongsaengmyeong-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do S.Korea
- Phone
- (+82) 043.270.6059
- contactus@g2gbio.com









